The overexpression of miR-200c inhibited the proliferation of acquired EGFR-TKI-resistant non-small cell lung cancer cells [137] and overcame resistance to gefitinib by inhibiting PI3K/Akt signaling in non-small cell lung cancer cells [140]. Here, AKT1 is linked to non-small cell lung carcinoma.